Caribou shares rose 22% on Thursday after the company announced it had positive initial data showing a 100% overall response rate and 80% complete response rate for its five evaluable patients from the Phase I ANTLER trial (NCT04637763) assessing its lead candidate CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic, anti-CD19 CAR-T cell therapy derived from healthy donor T cells . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge